FGFR4 transmembrane domain polymorphism and cancer risk: A meta-analysis including 8555 subjects
FGFR4 transmembrane domain polymorphism and cancer risk: A meta-analysis including 8555 subjects
复制标题
FGFR4 跨膜结构域多态性与癌症风险：一项包含 8555 名受试者的荟萃分析
DOI：
10.1016/j.ejca.2010.06.017
复制
发表时间：
2010-12-01
影响因子：
8.4
通讯作者：
Wu, Jianqing
中科院分区：
文献类型：
--
作者：
Xu, Wei;Li, Yan;Wu, Jianqing
成纤维细胞生长因子受体4(FGFR4)属于受体酪氨酸激酶家族，参与肿瘤的发生和发展。该受体跨膜区的FGFR4 Gly388Arg多态与肿瘤的遗传易感性有关，但结果并不一致。我们使用12项符合条件的病例对照研究进行了荟萃分析，共涉及4892名患者和3663名对照，以总结FGFR4 Gly388Arg多态与癌症风险之间的关联数据。在纯合子比较、等位基因对比和隐性遗传模型下，总体优势比(OR)95%可信区间(CI)显示FGFR4 Gly388Arg多态与癌症风险有统计学关联。在按种族划分的亚组分析中，在纯合子比较(OR=1.43，95%CI=1.13-1.80，P-异质性=0.24)、等位基因对比(OR=1.16，95%CI=1.04-1.29，P-异质性=0.25)和隐性遗传模式(OR=1.47，95%CI=1.19-1.81，P-异质性=0.15)方面，亚洲人患癌症的风险显著增加。在不同肿瘤类型的亚组分析中，Arg(388)等位基因对乳腺癌(纯合子比较OR=1.57，95%CI=1.04~2.37，P-异质性=0.83；隐性模型OR=1.51，95%CI=1.02-2.24，P-异质性=0.80)和前列腺癌(Gly/Arg与Gly/Gly：OR=1.16，95%CI=1.02-1.32，P-异质性=0.74)有增加作用；精氨酸与甘氨酸：OR=1.17，95%CI=1.07-1.29，P-异质性=0.18；优势模型：OR=1.20，95%CI=1.06-1.35，P-异质性=0.89)。我们的荟萃分析表明，FGFR4 Gly388Arg多态很可能导致癌症易感性，特别是在亚洲人中。此外，Arg388等位基因可能与乳腺癌和前列腺癌风险增加有关。(C)2010爱思唯尔有限公司。保留所有权利。
Fibroblast growth factor receptor 4 (FGFR4), belonging to the receptor tyrosine kinase family, is involved in cancer initiation and progression. The FGFR4 Gly388Arg polymorphism in the transmembrane domain of the receptor was shown to contribute to genetic susceptibility to cancer but the results were inconsistent. We performed a meta-analysis using 12 eligible case-control studies with a total of 4892 patients and 3663 controls to summarise the data on the association between the FGFR4 Gly388Arg polymorphism and cancer risks. The overall odds ratio (OR) with a 95% confidence interval (CI) showed statistical association between the FGFR4 Gly388Arg polymorphism and cancer risks under homozygote comparison, allele contrast and the recessive genetic model. In the subgroup analysis by ethnicity, statistically significantly increased cancer risks were found among Asians for homozygote comparison (OR = 1.43, 95% CI = 1.13-1.80, P-heterogeneity = 0.24), allele contrast (OR = 1.16, 95% CI = 1.04-1.29, P-heterogeneity = 0.25) and the recessive genetic model (OR = 1.47, 95% CI = 1.19-1.81, P-heterogeneity = 0.15). In the subgroup analysis for different tumour types, Arg(388) allele had an effect of increasing the risks of breast (homozygote comparison OR = 1.57, 95% CI = 1.04-2.37, P-heterogeneity = 0.83 and the recessive model OR = 1.51, 95% CI = 1.02-2.24, P-heterogeneity = 0.80) and prostate cancer (Gly/Arg versus Gly/Gly: OR = 1.16, 95% CI = 1.02-1.32, P-heterogeneity = 0.74; Arg versus Gly: OR = 1.17, 95% CI = 1.07-1.29, P-heterogeneity = 0.18 and the dominant model: OR = 1.20, 95% CI = 1.06-1.35, P-heterogeneity = 0.89). Our meta-analysis suggests that the FGFR4 Gly388Arg polymorphism most likely contributes to susceptibility to cancer, especially in Asians. Besides, the Arg388 allele might be associated with increased risks of breast and prostate cancer. (C) 2010 Elsevier Ltd. All rights reserved.